Feb 11 (Reuters) - CSL Ltd (CSL) :
- PRIVIGEN® (IMMUNE GLOBULIN INTRAVENOUS (HUMAN), 10% LIQUID) GRANTED ORPHAN-DRUG DESIGNATION FOR THE INVESTIGATIONAL TREATMENT OF SYSTEMIC SCLEROSIS (SSC)
News: CSL CSL's Privigen Granted Orphan-Drug Designation For The Investigational Treatment Of...
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$275.50 |
Change
-0.300(0.11%) |
Mkt cap ! $133.1B | |||
| Open | High | Low | Value | Volume |
| $276.76 | $277.00 | $275.36 | $128.2M | 465.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $275.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $275.68 | 189 | 1 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$275.43 |
Change
-0.300 ( 0.30 %) |
||||
| Open | High | Low | Volume | ||
| $276.39 | $277.00 | $275.39 | 183080 | ||
| Last updated 15.59pm 06/05/2024 ? | |||||
| CSL (ASX) Chart |